Tadalafil Market Will Generate Record Revenue by 2029
Tadalafil Market is expected to grow at a significant CAGR during the forecast period. The key companies operating in the industry are highly inclined towards the adoption of different growth strategies including partnerships and collaborations, mergers and acquisitions, geographical expansion, and new product launches, to remain competitive in the marketplace. For instance, in December 2020, Glenmark Pharmaceuticals Ltd. (Glenmark), a research-led global pharmaceutical company, received final approval from the US Food and Drug Administration (US FDA) for Tadalafil Tablets USP, 2.5 mg, 5 mg, 10 mg, and 20 mg, the generic version of Eli Lilly and Company's Cialis Tablets, 2.5 mg, 5 mg, 10 mg, and 20 mg. The Cialis Tablets, 2.5 mg, 5 mg, 10 mg, and 20 mg market had annual sales of approximately $125.5 million, for the 12-month period ending November 2020.
In September 2021, IntelGenx
Corp. announced that Aquestive Therapeutics, Inc., its co-development and
commercialization partner for Tadalafil oral films for the treatment of
erectile dysfunction (ED) and benign prostatic hyperplasia (BPH), has signed a definitive
license and supply agreement. Securing this commercial relationship is a
critical milestone in creative collaboration with Aquestive, and it represents
yet another big step toward realising the shared objective of making Tadalafil
oral films available to men suffering from ED and BP. In February 2019, Teva
Pharmaceutical Industries Ltd. announced the launch of ALYQ in the US, a
generic version of ADCIRCA (tadalafil) tablets, 20 mg. ALYQ is a
phosphodiesterase 5 (PDE5) inhibitor used to improve exercise performance in
people with pulmonary arterial hypertension (PAH). High blood pressure in the
lungs' blood arteries is known as PAH. Teva has the largest portfolio of
FDA-approved generic pharmaceuticals on the market, with over 550 generic
medications accessible, and is the market leader in first-to-file
opportunities, with over 100 pending first-to-files in the US. Teva generics
are being used to satisfy one out of every seven generic prescriptions written
in the US. In the US, ADCIRCA generated roughly $490 million in annual sales in
November 2018.
To Request a Sample of our Report on Tadalafil Market: https://www.omrglobal.com/request-sample/tadalafil-market
Market Coverage
• The market number available for – 2022-2030
• Base year- 2022
• Forecast period- 2023-2030
Segment Covered-
By Product
By Application
Regions covered-
•
North America
•
Europe
•
Asia-Pacific
•
Rest of the World
Competitive Landscape:
Glenmark Pharmaceuticals Ltd., Eli, Lilly & Co., and Teva Pharmaceutical Industries
Ltd., among others.
Tadalafil Market Report by Segment
By Type
• Purity:98%
• Purity: >98%
By Application
• Erectile Dysfunction
• Benign Prostatic Hyperplasia
• Others
A
full Report of Tadalafil Market is Available @ https://www.omrglobal.com/industry-reports/tadalafil-market
Tadalafil Market Report by Region
North America
·
United States
·
Canada
Europe
·
UK
·
Germany
·
Spain
·
France
·
Italy
·
Rest of Europe
Asia-Pacific
·
India
·
China
·
Japan
·
South Korea
·
Rest of APAC
Rest of the World
·
Latin America
·
Middle East & Africa
Reasons to buy from us –
1. We cover more than
15 major industries, further segmented into more than 90 sectors.
2. More than 120
countries are for analysis.
3. Over 100+ paid
data sources mined for investigation.
4. Our expert
research analysts answer all your questions before and after purchasing your
report.
About Orion Market Research
Orion Market
Research (OMR) is a market research and consulting company known for its crisp
and concise reports. The company is equipped with an experienced team of
analysts and consultants. OMR offers quality syndicated research reports,
customized research reports, consulting and other research-based services. The
company also offer Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services
through another subsidiary Encanto Technologies.
Media
Contact:
Company
Name: Orion Market Research
Contact
Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact
no: +91 7803040404
Comments
Post a Comment